COMPANY RESEARCHProvides one-stop drug development, regulatory submissions, and CMC/process services, based on clinical and preclinical research capabilities.
Profile review: 2026-11-06 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY PRC Accounting Standards / consolidated | 868,644,086.02 | 30,494,240.6 Net income attributable to shareholders of the listed company | 87,008,316.54 | Original ↗ |
| 2026Q3 (YTD) 2026-09-30 | CNY PRC Accounting Standards / consolidated | 731,793,813.76 | 49,295,497.2 Net income attributable to shareholders of the listed company | -9,559,128.27 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
Provides one-stop drug development, regulatory submissions, and CMC/process services, based on clinical and preclinical research capabilities.
Listed as SZSE 300404; original 2025 annual and 2026Q3 (YTD) reports reviewed.
Offers clinical operations and China–US registration services, with US development through BioTrialMed. For inbound China work, confirm local delivery, English communication and quality responsibilities separately.
International delivery scope: China-based / China-origin platform
IIT evidence: IIT capability not established by reviewed sources
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Integrated clinical and CMC CRO | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
The China National Center for Biotechnology Development published its fifteenth batch of biomedical clinical research filings on November 4. Seven projects completed filing between October 27 and November 4. The notice emphasizes institutional responsibility, internal quality management, training, data traceability, and participant protection. Filing concerns the research pathway; it is not evidence of therapeutic efficacy or product marketing authorization.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.